Insmed is one of those biotech names where the pipeline IS the story — and right now, that pipeline is generating real noise. The company's lead asset, brensocatib, just landed a high-profile collaboration with EMBARC on a landmark interventional study evaluating disease modification in bronchiectasis. That's not a press release placeholder. That's a serious academic partnership validating the drug's mechanism. Meanwhile, INSM is trading at $106.62 — well off its 200-day MA of $152.31 — which sets up an interesting tension: beaten-down price, improving clinical narrative.
Today's trade is a cash-secured put at the $105 strike expiring July 17, collecting $3.77 in premium with 16 days on the clock. That's a 3.7% return on capital at risk if INSM closes anywhere above $105 at expiration — roughly 87% annualized. The breakeven sits at $101.23, which is about 5% below current price. For a biotech with a delta of -0.417 and 30-day implied volatility running at 52.2%, you're being compensated reasonably well for the binary risk inherent in the name.
The fundamental picture is predictably messy for a clinical-stage biotech — a -144% profit margin is par for the course when you're burning cash on trials that cost nine figures. But the analyst community isn't running away: the consensus price target sits at $197, nearly double where INSM trades today. The stock's beta of 0.77 is surprisingly muted for a biotech, suggesting institutional holders aren't prone to panic-selling on minor headlines. The EMBARC collaboration and the recent appointment of a Senior VP for Global Respiratory suggest the commercial infrastructure is getting built ahead of what they expect to be a significant launch.
The technical setup is the honest part of this trade. INSM is trading below both its 50-day ($113.56) and 200-day ($152.31) moving averages — it's been in a sustained downtrend. This isn't a momentum play. It's a "has the selling been exhausted near this level" play. The $105 strike sits just below a round-number support zone, and with 16 DTE, there's limited time for macro noise to compound against the position. You're not betting on a recovery — you're collecting premium while waiting to see if the floor holds.
Watch the clinical calendar. Any update on the EMBARC study timeline, FDA interactions, or brensocatib enrollment data between now and July 17 could move this name sharply in either direction. Binary biotech risk is real — this trade is sized accordingly.
Today's Atlas Trades
UBER — Short Put
- Strike: $70.0
- Expiration: 2026-07-31
- Premium: $2.34
- Stock Price: $72.16
- IV: 41.8%
- Delta: -0.367
- DTE: 30
PTEN — Short Put
- Strike: $9.0
- Expiration: 2026-07-17
- Premium: $0.29
- Stock Price: $9.18
- IV: 49.8%
- Delta: -0.398
- DTE: 16
ETN — Short Put
- Strike: $410.0
- Expiration: 2026-07-17
- Premium: $10.9
- Stock Price: $426.12
- IV: 51.8%
- Delta: -0.336
- DTE: 16
VIR — Short Put
- Strike: $10.0
- Expiration: 2026-07-17
- Premium: $0.35
- Stock Price: $10.19
- IV: 52.4%
- Delta: -0.405
- DTE: 16
AVGO — Short Put
- Strike: $335.0
- Expiration: 2026-07-31
- Premium: $9.95
- Stock Price: $377.75
- IV: 64.6%
- Delta: -0.224
- DTE: 30
PLTR — Short Put
- Strike: $105.0
- Expiration: 2026-07-31
- Premium: $3.17
- Stock Price: $116.67
- IV: 61.2%
- Delta: -0.240
- DTE: 30
KMX — Short Put
- Strike: $45.0
- Expiration: 2026-08-21
- Premium: $1.3
- Stock Price: $52.89
- IV: 57.4%
- Delta: -0.188
- DTE: 51
FDS — Short Put
- Strike: $220.0
- Expiration: 2026-07-17
- Premium: $6.46
- Stock Price: $230.08
- IV: 58.0%
- Delta: -0.329
- DTE: 16
PPC — Short Put
- Strike: $27.9
- Expiration: 2026-07-17
- Premium: $0.86
- Stock Price: $28.11
- IV: 42.0%
- Delta: -0.441
- DTE: 16
TALO — Short Put
- Strike: $12.5
- Expiration: 2026-07-17
- Premium: $0.31
- Stock Price: $12.91
- IV: 47.0%
- Delta: -0.347
- DTE: 16
PYPL — Short Put
- Strike: $43.0
- Expiration: 2026-07-31
- Premium: $1.35
- Stock Price: $43.18
- IV: 30.6%
- Delta: -0.450
- DTE: 30
INSM — Short Put
- Strike: $105.0
- Expiration: 2026-07-17
- Premium: $3.77
- Stock Price: $106.62
- IV: 52.2%
- Delta: -0.417
- DTE: 16